HSP90AA1 and cancer: In response to HSP90 inhibition, the co‐chaperone CDC37 dissociates from RPAP2 and promotes the rapid degradation of RPAP2 via CRL5FBXW7, thereby enhancing the sensitivity of cancer cells to HSP90 inhibitors.